

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933

MIM Corporation
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

05-0489664
(I.R.S. Employer Identification No.)

100 Clearbrook Road, Elmsford, New York 10523
(Address of Principal Executive Offices) (Zip Code)

1999 CHIEF EXECUTIVE OFFICER EMPLOYMENT AGREEMENT
1998 PRESIDENT AND CHIEF OPERATING OFFICER EMPLOYMENT AGREEMENT
(Full Title of the Plan)

Barry A. Posner, Vice President and General Counsel
MIM Corporation, 100 Clearbrook Road, Elmsford, New York 10523
(914) 460-1600
(Name, address and telephone number, including area code, of agent for service)

Approximate date of commencement of the proposed sale to the public:
From time to time after the Registration Statement becomes effective.

=====

CALCULATION OF REGISTRATION FEE

=====

Title of Securities to be Registered	Amount to be Registered	Proposed Maximum Offering Price Per Share	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
Common Stock, \$0.0001 par value.....	2,100,000 shares	\$4.50 (1)	\$9,450,000 (1)	\$ 2,864 (1)

(1) Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee based on the registration hereunder of 2,100,000 shares of Common Stock that are the subject of options and restricted stock previously granted by the Company to two of the executive officers of the Company. In accordance with Rule 457(h), with respect to options previously granted by the Company, the registration fee has been computed based upon the exercise price of such options (\$4.50 in each case), and with respect to restricted stock previously granted by the Company, the registration fee has been computed based upon the average of the high and low sales prices of the Common Stock on the date of grant (\$4.50) in accordance with Rule 457(c).

EXPLANATORY NOTE

MIM Corporation, a Delaware corporation (the "Company"), entered into an employment agreement on December 2, 1998 with Mr. Richard H. Friedman, the Company's Chairman and Chief Executive Officer. Under his employment agreement, the Company granted Mr. Friedman an option to purchase 800,000 shares of common stock, \$0.0001 par value per share, of the Company (the "Common Stock"), and 300,000 shares of Common Stock subject to restrictions on transfer and encumbrance through December 2, 2006 ("Restricted Shares"). On April 17, 1998, the Company entered into an employment agreement with Mr. Scott R. Yablon, the Company's President and Chief Operating Officer. Under his employment agreement, the Company granted Mr. Yablon an option to purchase 1,000,000 shares of Common Stock. Neither the shares of Common Stock reserved for issuance upon the exercise of options granted under the employment agreements nor the Restricted Shares have been previously registered under the Securities Act of 1933, as amended (the "Act"). The Company has issued the options and Restricted Shares under the employment agreements pursuant to an exemption from registration under the Act. See Item 7.

This Registration Statement on Form S-8 (this "Registration Statement") is intended to register the following securities for issuance by the Company:

1. 800,000 and 1,000,000 shares of Common Stock that may be issued by the Company pursuant to the exercise of outstanding options previously awarded by the Company under the employment agreements of Messrs. Friedman and Yablon, respectively.

In accordance with General Instruction C.1(b) to Form S-8, this Registration Statement, together with the reoffer prospectus constituting a part hereof, are intended to register the following securities for reoffer and/or resale by Messrs. Friedman and Yablon, as the case may be:

1. 800,000 and 1,000,000 shares of Common Stock that may be issued by the Company pursuant to the exercise of outstanding options previously awarded by the Company under the employment agreements of Messrs. Friedman and Yablon, respectively; and

2. 300,000 Restricted Shares that have been issued by the Company to Mr. Friedman and with respect to which the restrictions on transfer and encumbrance have lapsed on or before December 2, 2006.

The materials constituting the reoffer prospectus have been prepared pursuant to Part I of Form S-3, in accordance with General Instruction C to Form S-8.

REOFFER PROSPECTUS

Up To 2,100,000 Shares

MIM CORPORATION

Common Stock

This Prospectus relates to the up to 2,100,000 shares of our Common Stock which the people identified under "Selling Stockholders" may offer and sell from time to time in one or more types of transactions (which may include block transactions) on The Nasdaq Stock Market's National Market Tier, where our Common Stock is listed for trading under the symbol "MIMS," in other markets where our Common Stock is traded, in negotiated transactions, through put or call options transactions, through short sales transactions, or in a combination of such methods of sale. They will sell the Common Stock at prices which are current when the sales take place or at other prices to which the parties agree. The Selling Stockholders may or may not use brokers and dealers in these transactions. The respective Selling Stockholders will pay any brokerage fees or commissions relating to sales by them. See "Method of Sale."

We may issue these shares of Common Stock to the Selling Stockholders upon the exercise by the Selling Stockholders of options we have previously awarded to them. In addition, we have issued to one of the Selling Stockholders shares of our Common Stock which are subject to restrictions on transfer and encumbrance for a specified period of time.

We will not receive any of the proceeds from any sales by the Selling Stockholders. We will pay all of the expenses associated with the registration of the Common Stock and this Prospectus.

On May 26, 1999, the last reported sale price of the Common Stock on Nasdaq was \$2.75 per share.

See "Risk Factors" beginning on page 3 of this Prospectus for a discussion of certain risks and other factors that you should consider before purchasing our Common Stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, and they have not determined if this Prospectus is truthful and complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus is May 27, 1999.

We have not authorized anyone to give any information or to make any representation which is not contained in this Prospectus or in a document incorporated by reference into this Prospectus. If anyone gives any information or makes any representation which is not contained in, or incorporated into this Prospectus, you must not rely upon it as having been authorized by us or by anyone acting on our behalf. This Prospectus is not an offer to sell, or a solicitation of an offer to buy, our securities by any person in any jurisdiction in which it is unlawful for that person to make such an offer or solicitation. No matter when you receive this Prospectus or purchase securities to which it relates, you must not assume it is correct at any time after its date.

TABLE OF CONTENTS

Heading: -----	Page Number -----
The Company	3
Risk Factors	3
Selling Stockholders	9
Use of Proceeds	9
Method of Sale	9
Indemnification of Directors and Officers.....	10
Where You Can Find More Information.....	11
Documents Incorporated By Reference	11
Legal Matters	12
Experts	12
Annex I - Selling Stockholders.....	13

THE COMPANY

We are an independent pharmacy benefit management ("PBM") and prescription mail order organization that offers a broad range of pharmaceutical services to the health care industry. We promote the cost effective delivery of pharmacy benefits to both public and private health plan members as well as the general public. We target two types of plan sponsors:

- o sponsors of public and private health plans, such as:
 - o health maintenance organizations ("HMO's")
 - o other managed care organizations ("MCO's") and
 - o long-term care facilities, such as nursing homes and assisted living facilities and
- o self-funded plans sponsored by employers.

We provide flexible program designs, pricing arrangements, formulary management, clinical expertise, innovative technology and quality services designed to contain pharmacy costs. We promote the clinically appropriate substitution of generic drugs from equivalent but more expensive brand name drugs that are often prescribed.

We were incorporated in Delaware in March 1996 and completed our initial public offering in August 1996. Prior to our offering, we combined the businesses and operations of Pro-Mark Holdings, Inc. and MIM Strategic Marketing, LLC, which became 100% and 90% owned subsidiaries, respectively, of ours in May 1996. On August 24, 1998, we acquired all of the outstanding capital stock of Continental Managed Pharmacy Services, Inc., complementing our core PBM business with mail order pharmacy services.

Our principal executive offices are located at 100 Clearbrook Road, Elmsford, New York 10523, telephone number (914) 460-1600. Unless the context otherwise requires, all references to "we", "us", "our" or "the Company" refers to MIM Corporation and its predecessors and subsidiaries.

RISK FACTORS

Before you purchase any Common Stock, you should be aware that there are various risks associated with an investment in the Common Stock, including those described below. You should consider carefully these risk factors together with the other information included in this Prospectus in evaluating whether to purchase any Common Stock

Actual Results May Vary Materially From Results Associated With Forward-Looking Statements

Some of the information contained in, or incorporated by reference into this Prospectus includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include the information concerning our possible or assumed future results of operations as well as statements preceded by, followed by or that include the words "may," "will," "could," "would," "believe," "expect," "anticipate," "estimate," "intend," "project" or the negative thereof or other similar expressions. You are cautioned that any forward-looking statements are not guarantees of future performance and involve risks and uncertainties. When considering such forward-looking statements, you should keep in mind the risk factors listed below and other cautionary statements contained in, or incorporated by reference into this Prospectus. The risk factors noted in this section and other factors noted throughout the Prospectus, including certain risks and uncertainties, could cause our actual results to differ materially from those results associated with any forward-looking statement. We do not undertake any obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect any future events and circumstances.

Adverse Events With Respect To TennCare Program or Our Relationship With TennCare Plan Sponsors Could Adversely Affect Us

In January 1994, the State of Tennessee instituted its Medicaid demonstration waiver program referred to as "TennCare." The State of Tennessee contracted with certain MCO's to provide mandated health services to TennCare beneficiaries on a capitated basis. In turn, certain of these MCO's contracted with RxCare of Tennessee, Inc. ("RxCare") to provide TennCare mandated pharmaceutical benefits to their TennCare beneficiaries through RxCare's network of retail pharmacies, in most cases on a corresponding capitated basis.

From January 1994 through December 31, 1998, we provided a broad range of PBM services to these TennCare beneficiaries under an agreement with RxCare (the "RxCare Contract"). Under the RxCare Contract, we also provided PBM services to commercial plan sponsors and their enrollees. We performed essentially all of RxCare's obligations under its PBM contracts with plan sponsors, including designing and marketing PBM programs and services. Under the RxCare Contract, we paid certain amounts to RxCare and shared with RxCare the profit, if any, derived from services performed under RxCare's contracts with the plan sponsors.

As of December 31, 1998, we serviced six TennCare plan sponsors with approximately 1.2 million members under the RxCare Contract. The RxCare Contract accounted for 72.2% of our revenues for the year ended December 31, 1998 and approximately 83.6% of our revenues for the year ended December 31, 1997. RxCare's contracts with Tennessee Managed Care Network, Inc., Tennessee Behavioral Health, Inc., Premier Behavioral Systems of Tennessee and Phoenix Healthcare of Tennessee accounted for approximately 16%, 11%, 16% and 12%, respectively, of our revenues in 1998.

The Company and RxCare did not renew the RxCare Contract which expired on December 31, 1998. The negotiated termination of our relationship with RxCare, among other things, allowed us to directly market its services to Tennessee customers (including those then under contract with RxCare) prior to the expiration of the RxCare Contract. The RxCare Contract had previously prohibited us from soliciting and/or marketing our PBM services in Tennessee other than on behalf of, and for the benefit of RxCare. Our marketing efforts after the negotiated termination resulted in us executing agreements effective as of January 1, 1999 to provide PBM services directly to five of the six TennCare MCO's representing approximately 900,000 of the 1.2 million TennCare lives previously managed under the RxCare Contract. In addition, effective May 1, 1999, we entered into a contract to provide PBM services to the sixth TennCare MCO we managed under the RxCare Contract and its approximately 300,000 enrollees, thereby contracting with all of the TennCare MCO's we formerly managed through the RxCare Contract until December 31, 1998. Effective January 1, 1999, we also contracted directly to provide PBM services to substantially all third party administrators and employer groups previously managed under the RxCare Contract. We anticipate that approximately 45% of our revenues for fiscal 1999 will be derived from providing PBM services to these six TennCare MCO's. To date, we have been unable to secure a contract with the two TennCare behavioral health organizations ("BHO's") to which we previously provided PBM services under the RxCare Contract. For the year ended December 31, 1998, amounts paid by these BHO's represented approximately 27% of our revenues. Accordingly, our failure to eventually obtain contracts with the two BHO's or the loss of any of the other TennCare contracts we presently have, if not replaced by other business, could materially adversely affect our financial condition and results of operations.

As part of our normal review process, in April 1999 we determined that two of our capitated TennCare contracts were not achieving profitability projections. Accordingly, in accordance with the terms of these contracts, we exercised our right to terminate these contracts effective on September 28, 1999. Representatives of the Company and these TennCare MCO's are presently renegotiating these contracts. While we believe that it is reasonably likely that the terms of these contracts will be renegotiated, no assurance can be given that we will successfully renegotiate the contracts with either or both of these customers. In addition, no assurance can be given that we will not incur losses under either or both of these contracts during the interim period until termination becomes effective.

Certain Legal Proceedings Could Adversely Affect Our Liquidity

In February 1999, we reached an agreement in principle with respect to a civil settlement of a Federal and State of Tennessee investigation focusing mainly on the conduct of two former officers (one of which is also a former director and still a principal stockholder) prior to our initial public offering. Based upon the agreement in principle, the investigation, as it relates to us, would be fully resolved through the payment of a \$2.2 million civil settlement and an agreement to implement a corporate integrity program in conjunction with the Office of the Inspector General of the U.S. Department of Health and Human Services. This settlement is subject to several conditions, including the execution of a definitive agreement. We anticipate that we will have no continued involvement in the governments' joint investigation other than continuing to cooperate with the governments in their efforts.

On March 31, 1999, Xantus Healthplan of Tennessee, Inc. ("Xantus"), one of the TennCare MCO's to which we provide PBM services, and the State of Tennessee entered into a consent decree whereby, among other things, the Commissioner of Commerce and Insurance for the State of Tennessee was appointed receiver of Xantus for purposes of rehabilitation. The receiver has begun to pay in a timely manner all amounts due to us under our agreement with Xantus for services rendered by the Company from and after April 1, 1999. As of the date of this Prospectus, we continue to provide PBM services to Xantus and its members under our agreement with them. At this time, we are unable to predict the consequences of this action on our ability to collect monies owed to us by Xantus. As of April 1, 1999, Xantus owed us \$10.7 million relating to PBM services rendered by us from January 1, 1999 through April 1, 1999. To date, we have withheld from our pharmacy providers approximately \$4.0 million (out of approximately \$10 million) of claims submitted by them on behalf of Xantus members as permitted by our agreements with these pharmacy providers. If and when we are paid by Xantus with respect to these claims, we will pay our network pharmacies for these claims. State of Tennessee officials have publicly indicated that the State will ensure that all TennCare providers negatively impacted by the appointment of the receiver for Xantus will eventually receive from Xantus or the State at least 50% of all outstanding amounts owed by Xantus to such providers as of April 1, 1999. We can give no assurance that Xantus or the State will eventually pay any or all of these amounts. Our failure to collect from Xantus or the State all or a substantial portion of the monies owed to us by Xantus would have a material adverse effect on our financial condition and results of operations.

Under Section 145 of the Delaware General Corporation Law ("Section 145") and the Company's Amended and Restated By-Laws ("By-Laws"), we are obligated to indemnify two former officers (one of which is also a former director and still a principal stockholder) who are the subject of the indictments brought in the United States District Court for the Western District of Tennessee (as more fully described in our Annual Report on Form 10-K for the fiscal year ended December 31, 1998). Our obligation to provide indemnification would not apply if it is ultimately determined by our Board of Directors that these former officers failed to act in good faith and in a manner they reasonably believed to be in our best interests, that they had reason to believe that their conduct was unlawful or for any other reason under which indemnification would not be required under Section 145 or the By-Laws. In addition, until the Board makes such a determination, we are also obligated under Section 145 and the By-Laws to advance the costs of defense to them. However, if the Board determines that either or both of them are not entitled to indemnification, they would be obligated to reimburse us for all amounts advanced to them. We are not presently in a position to assess the likelihood that either or both of these former officers will be entitled to indemnification and continued advancement of defense costs or to estimate the total amount that we may have to pay in connection with our obligations or the time period over which any amounts will have to be advanced. We cannot assure you that our obligations to either or both of these former officers would not have a material adverse effect on our results of operations or financial condition.

Limited Term of Material Agreements Could Adversely Affect Us

Our contracts with plan sponsors typically have terms of one to three years and are subject to earlier termination upon the occurrence of certain events, including a breach of an agreement which is not cured within a reasonable time after notice, insolvency, bankruptcy or receivership of the plan and termination of the underlying health care program (for example, TennCare) or of the plan sponsor's contract with the ultimate payor. In certain

cases, both us and the plan sponsor may also terminate the agreement without cause, typically upon prior written notice, generally 30 to 90 days, but in some cases as long as 150 days. We cannot guarantee that any contracts with plan sponsors will be continued or renewed in accordance with their terms. The loss of any particular plan sponsor contract, especially those with the TennCare MCO's, or the loss of a significant number of them, could have a material adverse effect on our financial condition and results of operations. As discussed above, we are presently in the process of attempting to renegotiate capitated contracts with two TennCare MCO's following our delivery of notices of termination of these two contracts that will become effective on September 28, 1999, unless we successfully renegotiate these contracts.

Risk-Based Arrangements Could Adversely Affect Us

For the year ended December 31, 1998, approximately 32% of our revenues were generated from capitated or other risk-based arrangements, compared to 53% for the year ended December 31, 1997. Effective January 1, 1999, we began providing PBM services directly to five of the six TennCare MCO's previously managed under the RxCare Contract. Effective May 1, 1999, we began providing PBM services to the sixth TennCare MCO previously managed under the Rx Care Contract. We will be compensated on a capitated basis under four of the six TennCare contracts, thereby increasing our financial risk in 1999 as compared to 1998. Based upon our present contracted arrangements, we anticipate that approximately 36% of our revenues in 1999 will be derived from capitated or other risk-based arrangements.

Under "capitated" arrangements, we receive a pre-determined fee each month for each member enrolled in a particular health plan in return for providing certain covered pharmacy benefits and services to plan members. From time to time, we may also enter into cost sharing arrangements (i.e., sharing with plan sponsors the financial benefits resulting from not exceeding established per capita amounts), profit sharing arrangements (i.e., incentivizing the plan sponsors to support fully our cost control efforts as well as other arrangements under which we may share all or a portion of the risk of the drug benefit program with the plan sponsor). We generally negotiate capitation fees and other risk-based arrangements for a particular plan (or subset of individuals within a plan) based upon a number of factors, including competitive conditions within a particular market, the expected costs of providing the covered pharmacy services, anticipated price increases for pharmaceutical products and anticipated increases in the utilization of those products by plan members. The cost of providing pharmacy services varies among plan participants and groups and is affected by many factors largely beyond our control, including compliance by physicians and patients with the drug formulary and benefit design parameters, the acceptance rate of substitution of generic drugs for higher priced brand name drugs, especially in light of the dramatic increase in direct consumer marketing of brand name drugs, the effect of inflation on drug costs, higher than expected utilization rates and the co-payment structure of the plan. We generally base our expected costs on prior experience with similar groups and demographic data based on the population at large. Data with respect to prior experience may not be available and, if available, may not be a reliable indicator of the actual results for a particular plan. In addition, under these risk-based arrangements, we may be required to bear all or a portion of the costs of certain newly-developed drugs the existence or cost of which may not have been known at the time the capitation fee or other risk-based arrangement for a particular plan was established. We cannot guarantee that the cost of providing pharmacy services under capitated or other risk-based arrangements will not exceed the revenues received by us with respect to those arrangements. Any shortfall between revenues received and costs incurred under these capitated and other risk-based arrangements could have a material adverse effect on the Company's financial condition and results of operations. For example, on April 30, 1999, we gave notice of termination to two of the TennCare MCO's to which we began providing services on a capitated basis as of January 1, 1999 due to forecasted losses under those contracts. See "Adverse Events With Respect to TennCare Program or our Relationship With TennCare Plan Sponsors Could Adversely Affect Us."

We Have Had Historical Accounting Losses And May Experience Future Losses

We experienced losses of approximately \$13.5 million, \$31.8 million, \$6.8 million and \$2.5 million in the years ended December 31, 1997, 1996, 1995 and 1994, respectively. For the year ended December 31, 1998, we

reported net income of \$4.3 million, after recording non-recurring charges of \$3.7 million. These historical results are not indicative of future results, but we cannot assure you that we will not incur net losses in the future.

Rapid Growth and Integration of Acquired Businesses May Be Difficult to Manage Efficiently

Since we went public in August 1996, we have been attempting to grow at a rapid pace. Rapid growth may strain our financial and management resources. Our ability to manage growth effectively will require that we continue to identify, hire, train and effectively manage additional qualified employees. We cannot assure you that we will be able to expand our market presence in current locations or successfully enter other markets. If we are unable to manage our growth effectively and efficiently, our financial condition and results of operations could be adversely affected.

Our current strategy contemplates the continued growth of our company through mergers and acquisitions of other companies and business entities which engage in PBM and other related services as well as other strategic arrangements. However, any business acquisition or other strategic arrangement involves inherent uncertainties, such as the effect on the acquired business of integration into a larger organization and the availability of management resources to oversee the integration and operation of the acquired business. Potential obstacles to the successful integration of the acquired business include, among others, consolidating financial, accounting and managerial functions and eliminating operational overlaps between our businesses, and adding and integrating key personnel. Even though the acquired businesses may have been successful as independent companies prior to the merger, acquisition or strategic arrangement, we cannot assure you that their success will continue afterwards.

Larger Competitors May Adversely Affect Our Ability to Compete Effectively

The PBM industry is highly competitive and has recently experienced significant consolidation. Many of our current and potential competitors have considerably greater financial, technical, marketing and other resources. The PBM business includes a number of large, well capitalized companies with nationwide operations and many smaller organizations typically operating on a local or regional basis. Among larger companies offering PBM services are Medco Containment Services, Inc. (a subsidiary of Merck & Co., Inc.), PCS, Inc., Express Scripts, Inc., Advance Paradigm, Inc. and Diversified Pharmaceutical Services, Inc. Numerous insurance and Blue Cross and Blue Shield plans, managed care organizations and retail drug chains also have their own PBM capabilities.

We May Not Be Able to Retain Key Management

Our success is largely dependent on the services of Richard H. Friedman, our Chief Executive Officer, and, to a lesser extent, other key management personnel. We have an employment agreement with Mr. Friedman which provides for his continued employment through December 2003, subject to earlier termination under certain circumstances. We cannot guarantee that we will be able to retain his services or the services of any other key management personnel. The loss of the services of one or more of our senior management could have a material adverse effect upon our financial condition and results of operations.

Our Failure to Comply With Laws and Regulations Could Adversely Affect Us

Our present and planned businesses are subject to extensive federal and state laws and regulations. Subject to certain exceptions, federal law (the "Federal Anti-Kickback Statute") prohibits the payment or receipt of any remuneration, directly or indirectly, to induce, arrange for or recommend the purchase of health care items or services paid for in whole or in part by Medicare or state health care programs (including Medicaid and TennCare). In addition, certain state laws (including professional licensing laws prohibiting fee-splitting) contain similar provisions that may extend the prohibition to cover items or services that are paid for by private insurance and self-pay patients. We can make no assurance that our practices will be found to be protected by certain so-called "safe harbor" regulations, which provide insulation from prosecution under the Federal Anti-Kickback Statute, and in some instances it is clear that they are not so protected. We are also subject to various false claim, drug distribution, antitrust and consumer protection laws and may be subject to certain other laws, including

various state insurance laws.

While management believes that we are in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are subject to rapid change and often are uncertain in their application. As controversies continue to arise in the health care industry (for example, regarding the efforts of plan sponsors and pharmacy benefit managers to limit formularies, alter drug choice and establish limited networks of participating pharmacies), federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which we cannot currently predict. It is possible that we will be subject to scrutiny or challenge under one or more of these laws or that any such challenge might be successful. Any such challenge, whether or not successful, could have a material adverse effect upon our financial position and results of operations. Violation of the Federal Anti-Kickback Statute, for example, may result in criminal penalties, as well as exclusion from the Medicare and Medicaid (including TennCare) programs. Further, it is possible that we will not be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material adverse effect on our financial condition and results of operations.

The Services We Provide May Subject Us to Litigation and Liability

We believe that our insurance protection is adequate to protect us from litigation and liability in connection with our present and contemplated business operations. However, we cannot assure you that we will be able to obtain and maintain insurance coverage in the future or that such insurance coverage will be available on acceptable terms or will be adequate to cover any or all potential professional liability, product liability or other claims. A successful claim in excess of our insurance coverage could have a material adverse effect on our financial condition and results of operations.

Our Dependence on Information Systems and the Year 2000 Issue Could Adversely Affect Us

We believe our on-line claims processing (or adjudication) systems are an integral part of our business. We own our claims processing software and have an agreement to acquire all software upgrades to such software to ensure that we maintain a state-of-the-art claims processing system. Any significant interruption in service of our computer or telephone systems could adversely affect our ability to operate our business on a timely basis, and could adversely affect our relations with our pharmacies and health plan sponsors. Under a contract with a third party, the third party guarantees that any disruption in our computer or telephone systems will be rectified within 48 hours. Although we cannot guarantee it, we believe that this disaster recovery arrangement is sufficient to prevent any disruption from having a material adverse effect on our financial condition or results of operations.

The so-called "year 2000 problem," which is common to many companies, concerns the inability of information systems, primarily computer hardware and software programs, to recognize properly and process date sensitive information following December 31, 1999. We have committed substantial resources (approximately \$2.4 million) over the past two years to improve our information systems ("IS project"). We have used this IS project as an opportunity to evaluate our state of readiness, estimate expected costs and identify and quantify risks associated with any potential year 2000 issues. For a detailed discussion of these matters, see "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 1998.

Possible Negative Effects on Stockholders of Preferred Stock and Rights

We are authorized to issue 5,000,000 shares of preferred stock. Our Board of Directors may from time to time fix the designation, rights and preferences of preferred stock (including voting, dividend, redemption and liquidation rights) without further stockholder action. Shares of preferred stock could be issued in the future with rights and preferences that could make the possible takeover of the Company or the removal of management more difficult or could otherwise adversely impact the rights of stockholders.

On November 24, 1998, the Board adopted a stockholder rights plan. The rights plan may have certain anti-takeover effects and may cause substantial dilution to a person or group that attempts to acquire the Company on terms not approved by the Board. The stockholder rights plan was adopted to help ensure that the Board, if confronted by an unsolicited proposal from a third party to acquire control of the Company, will have sufficient time to review the proposal, to develop, if deemed appropriate, alternatives to the proposal and to act in what the Board believes to be in the best interests of the Company and its stockholders.

As originally adopted, the rights plan contains a "delayed redemption" provision that prohibited rights under the plan from being redeemed by us during the 180-day period after "continuing directors" (as defined in the rights plan) cease to constitute a majority of the Board. This provision effectively prevented newly-elected directors, in a change in control context, from redeeming rights for six months, thereby delaying any acquisition of the Company. In December 1998, the Delaware courts ruled in *Quickturn Design Systems, Inc. v. Mentor Graphics Corp.*, 721 A.2d 1281 (Del. 1998) that a similar provision was invalid under Delaware law. As a result, the Board has amended the rights plan to delete this "delayed redemption" provision. We may seek to take other actions to achieve the same objectives as the rights plan and the "delayed redemption" provision were implemented to address. Certain of these actions could require stockholder approval. We cannot assure you that we will or will not take or seek to take any such actions.

We Have Never Paid Dividends and Have No Current Intention to Pay Dividends

We have never paid a cash dividend on the Common Stock and presently intend to retain all earnings, if any, to support the operation and expansion of our business. We do not anticipate paying cash dividends in the foreseeable future.

Possible Volatility of Stock Price

The market price of the Common Stock has fluctuated substantially since our initial public offering. The price of the Common Stock may be subject to fluctuations in the future in response to operating results, general market movements and other factors. In addition, the Common Stock as well as the stock market in general has historically experienced price and volume fluctuations that often have been unrelated or disproportionate to the operating performance of the Company and companies in general. These fluctuations, as well as general economic and market conditions, may adversely affect the market price of the Common Stock.

SELLING STOCKHOLDERS

The table attached as Annex I hereto sets forth, as of the date of this Prospectus or a subsequent date if amended or supplemented, (a) the name of each Selling Stockholder and his or her relationship to the Company during the past three years; (b) the number of shares of Common Stock each Selling Stockholder beneficially owns (assuming that all options and restricted shares which they have previously been granted are fully vested and free from restrictions on transfer); (c) the number of shares of Common Stock offered pursuant to this Prospectus by each Selling Stockholder; and (d) the amount and percentage of the Common Stock outstanding to be held by such Selling Stockholder after giving effect to the offering of the Common Stock covered by this Prospectus. The information contained in Annex I may be amended or supplemented from time to time.

USE OF PROCEEDS

We will not receive any of the proceeds from the sale of Common Stock by Selling Stockholders covered by this Prospectus.

METHOD OF SALE

This Prospectus relates to the possible offer and sale from time to time by the Selling Stockholders of their shares of Common Stock which they may receive upon the exercise of options or which they may transfer upon the

lapse of restrictions on restricted shares. These options and restricted shares have been issued under employment agreements between the Company and such Selling Stockholders. We have registered their shares for resale to provide them with freely tradeable securities. However, registration of their shares does not necessarily mean that they will offer or sell any of their shares. We will not receive any proceeds from the offering or sale of their shares.

The Selling Stockholders may offer and sell the shares of Common Stock to which this Prospectus relates from time to time in one or more types of transactions (which may include block transactions) on The Nasdaq Stock Market's National Market Tier, where our Common Stock is listed for trading under the symbol "MIMS," in other markets where our Common Stock is traded, in negotiated transactions, through put or call options transactions, through short sales transactions, or in a combination of such methods of sale. They will sell the Common Stock at prices which are current when the sales take place or at other prices to which the parties agree. The respective Selling Stockholders may use underwriters, brokers or dealers to sell the shares, and will pay any brokerage fees or commissions relating to sales by them in amounts to be negotiated by them prior to sale. Such brokers or dealers and any other participating brokers or dealers may be deemed to be "underwriters" within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), in connection with such sales and any discounts and commissions received by them and any profit realized by them on the resale of the shares may be deemed to be underwriting discounts and commissions under the Securities Act. Some shares may also be sold by other people or entities which receive the shares from one or more of the Selling Stockholders by gift, by operation of law (including the laws of descent and distribution) or by other transfers or assignments.

Because the Selling Stockholders may be deemed to be "underwriters" within the meaning of the Securities Act, the Selling Stockholders will be subject to the prospectus delivery requirements of the Securities Act. We have informed the Selling Stockholders that the anti-manipulative provisions of Regulation M promulgated under the Exchange Act may apply to their sales in the market.

Selling Stockholders also may resell all or a portion of their shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided they meet the criteria and conform to the requirements of such Rule.

If we are notified by any Selling Stockholder that any material arrangement has been entered into with an underwriter, broker or dealer for the sale of shares through block trade, special offering, exchange distribution or secondary distribution or purchase by an underwriter, broker or dealer, we will prepare and file a supplement to this Prospectus, if required, under Rule 424(b) of the Securities Act, disclosing (i) the name of the respective Selling Stockholder(s) and of the participating broker-dealer(s), (ii) the number of shares involved, (iii) the price at which such shares were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set forth or incorporated by reference in this Prospectus and (vi) other facts material to the transaction.

INDEMNIFICATION OF DIRECTORS AND OFFICERS

Our Amended and Restated Certificate of Incorporation limits the liability of our directors to us or our stockholders to the fullest extent permitted by the Delaware General Corporation Law (the "DGCL"). Specifically, our directors will not be personally liable for monetary damages for breach of his fiduciary duty as a director except for liability (a) for any breach of his duty of loyalty to us or our stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) for unlawful payment of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL or (d) for any transaction from which he derived an improper personal benefit. In addition, our By-Laws require us to indemnify any current or former director or officer to the fullest extent permitted by the DGCL. We also maintain insurance for the benefit of our directors and officers and the directors and officers of our subsidiaries insuring such persons against certain civil liabilities, including liabilities under the securities laws.

AVAILABLE INFORMATION

We have filed a Registration Statement on Form S-8 (the "Registration Statement") with the Securities and Exchange Commission (the "Commission") under the Securities Act covering the securities (i) covered by this Prospectus and (ii) issuable upon the exercise of options and/or the lapse of transfer restrictions on restricted shares, in each case, previously awarded to the Selling Stockholders under employment agreements between them and the Company. This Prospectus omits certain information and exhibits included in the Registration Statement, copies of which may be obtained upon payment of a fee prescribed by the Commission or may be examined free of charge at the principal office of the Commission in Washington, D.C.

We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance with those requirements, we file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission (the "Commission"). You may read and copy those reports and proxy statements and any other information we file with the Commission at the public reference facilities maintained by the Commission at Room 1024, Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549, and at the Regional Offices of the Commission located at 7 World Trade Center, New York, New York 10048 and Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661. You may also obtain copies of that information from the Commission's Public Reference Section at 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. Please call the Commission at 1-800-SEC-0330 for further information on the public reference rooms. The Commission maintains a web site that contains reports, proxy and information statements and other information regarding registrants, including MIM Corporation, that file electronically with it. You may access the Commission's web site at "<http://www.sec.gov>". Our Common Stock is listed for trading on the Nasdaq Stock Market's National Market Tier. You may also read any such reports, proxy statements and other information filed or to be filed by us at the offices of the National Association of Securities Dealers, Inc., Market Listing Section, 1735 K Street, N.W., Washington, D.C. 20006.

DOCUMENTS INCORPORATED BY REFERENCE

We incorporate by reference into this Prospectus the following documents which we previously filed with the Commission under the File Number 0-28740:

- (a) Our Annual Report on Form 10-K for the fiscal year ended December 31, 1998;
- (b) Our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 1999; and
- (c) The description of the Company's Common Stock contained in the Company's Registration Statement on Form 8-A, filed pursuant to Section 12(g) of the Exchange Act on July 30, 1996, as amended by Post-Effective Amendment No. 1 on Form 8-A/A filed on August 1, 1996, and declared effective on August 14, 1996, as well as the description of the Company's Series A Junior Participating Preferred Stock Purchase Rights contained in the Company's Registration Statement on Form 8-A filed on December 4, 1998, as amended by Post-Effective Amendment No. 1 on Form 8-A/A filed on December 14, 1998, as amended by Post-Effective Amendment No. 2 on Form 8-A/A filed on May 20, 1999.

When we file documents in accordance with Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act between the date of this Prospectus and the time we file a post-effective amendment to the Registration Statement reporting that all the securities which are the subject of the Registration Statement have been sold or deregistering any securities which have not been sold, those documents we file will be incorporated into this Prospectus and will be a part of it beginning on the date those documents are filed. If any document which we file changes anything said in this Prospectus or in an earlier document which is incorporated into this Prospectus, the later document will modify or supersede what is said in this Prospectus or the earlier document.

We will provide, without charge, at the written or oral request of anyone to whom this Prospectus is delivered, copies of the documents incorporated by reference in this Prospectus, other than exhibits to those documents which

are not specifically incorporated by reference. Requests should be directed to: MIM Corporation, 100 Clearbrook Road, New York, New York 10523, Attention: Corporate Secretary (Telephone: (914) 460-1638).

LEGAL MATTERS

Barry A. Posner, our General Counsel, will pass upon certain legal matters for us.

EXPERTS

The financial statements incorporated by reference in this Registration Statement have been audited by Arthur Andersen LLP, independent public accountants, as indicated in their report with respect thereto, and are incorporated by reference herein in reliance upon the authority of said firm as experts in giving said report.

ANNEX I
SELLING STOCKHOLDERS (1)

Name	Relationships to the Company	Shares Beneficially Owned	Shares Offered Hereby	Shares Beneficially Owned After Offering: (2)	
				Number	Percentage
Richard H. Friedman	Chairman and Chief Executive Officer	2,600,000 (3)	1,100,000	1,500,000	8.0%
Scott R. Yablon	President, Chief Operating Officer and Director	1,222,000 (4)	1,000,000	20,000	5.3%

(1) Assumes that all options held by the listed individuals are fully vested and exercisable, although Mr. Friedman's options vest in equal installments on the first three anniversary dates of the date of grant and 75% of Mr. Yablon's options are fully vested and the remaining 25% vest on April 17, 2000. Also assumes that all restricted shares held are freely transferable without restriction, although such restrictions do not lapse until specified dates in the future. Shares deemed beneficially owned by virtue of these assumptions are treated as outstanding for purposes of determining beneficial ownership by such individual.

(2) Assumes the sale of all securities offered hereby. Based upon 18,771,689 shares of Common Stock outstanding on May 10, 1999.

(3) Includes options to purchase 800,000 shares of Common Stock and 300,000 shares of Common Stock subject to restrictions on transfer and encumbrance.

(4) Includes options to purchase 1,000,000 shares of Common Stock and 200,000 shares of Common Stock subject to restrictions on transfer and encumbrance.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

There are hereby incorporated by reference in this Registration Statement the following documents and information heretofore filed with the Securities and Exchange Commission (the "Commission"):

(a) The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1998, filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act");

(b) The Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 1999; and

(c) The description of the Company's Common Stock contained in the Company's Registration Statement on Form 8-A, filed pursuant to Section 12(g) of the Exchange Act on July 30, 1996, as amended by Post-Effective Amendment No. 1 on Form 8-A/A filed on August 1, 1996, and declared effective on August 14, 1996 as well as the description of the Company's Series A Junior Participating Preferred Stock Purchase Rights contained in the Company's Registration Statement on Form 8-A filed on December 4, 1998, as amended by Post-Effective Amendment No. 1 on Form 8-A/A filed on December 14, 1998, as amended by Post-Effective Amendment No. 2 on Form 8-A/A filed on May 20, 1999.

All reports and other documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports or documents. Statements made herein as to the contents of any contract, agreement or other document are not necessarily complete. With respect to each such contract, agreement or other document filed as an exhibit to this Registration Statement, reference is made to the exhibit for a more complete description of the matter involved, and each such statement shall be deemed qualified in its entirety by such reference.

Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers.

The Company's Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") limits the liability of the Company's directors to the Company or its stockholders to the fullest extent permitted by the Delaware General Corporation Law (the "DGCL"). Specifically, no director of the Company will be personally liable for monetary damages for a breach of such director's fiduciary duty as a director of the Company except for liability (a) for any breach of the director's duty of loyalty to the Company or its stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) for unlawful payment of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL or (d) for any transaction from which such director derived an improper personal benefit. In addition, the Company's Amended and Restated By-Laws (the "By-Laws") require the Company to indemnify any current or former director or officer to the fullest extent permitted by the DGCL. The Company also maintains insurance for the benefit of its directors and officers and the directors and officers of its subsidiaries insuring such persons against certain civil liabilities, including liabilities under the securities laws.

Item 7. Exemption from Registration Claimed.

On December 2, 1998, pursuant to a new employment agreement between the Company and Mr. Richard H. Friedman, Chairman and Chief Executive Officer of the Company, the Company granted Mr. Friedman, among other things, an option to purchase 800,000 shares of Common Stock and 300,000 Restricted Shares. The Restricted Shares will automatically be forfeited to the Company upon termination of Mr. Friedman's employment with the Company prior to December 2, 2006. The restrictions to which the Restricted Shares are subject may lapse prior to December 2, 2006 in the event that the Company achieves certain specified levels of earnings per share in fiscal 2001. Mr. Friedman possesses voting rights with respect to the Restricted Shares, but is not entitled to receive dividend or other distributions, if any, paid with respect to the Restricted Shares.

On April 17, 1998, pursuant to an employment agreement between the Company and Mr. Scott R. Yablon, President and Chief Operating Officer of the Company, the Company granted Mr. Yablon an option to purchase 800,000 shares of Common Stock.

The reoffer prospectus constituting a part of this Registration Statement covers the reoffer and/or resale by Messrs. Friedman and/or Yablon, as the case may be, of these 1,800,000 shares of Common Stock that may be issued by the Company pursuant to the exercise of outstanding options previously awarded by the Company under the employment agreements of Messrs. Friedman and Yablon, as well as the 300,000 Restricted Shares that have been issued by the

Company to Mr. Friedman and with respect to which the restrictions on transfer and encumbrance have lapsed on or before December 2, 2006.

The Company issued these options and Restricted Shares without registration under the Act pursuant to the exemption from registration provided by Section 4(2) of the Act.

Item 8. Exhibits.

Exhibit
Number

- 4.1 Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company's Registration Statement on Form S-1 (No. 333-05327)).
- 4.2 Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3(ii) of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 1998).
- 4.3 The Company's 1996 Stock Incentive Plan, as amended and restated effective as of December 1, 1998 (incorporated by reference to Exhibit 10.33 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1998).
- 4.4 The Company's 1996 Non-Employee Directors Stock Incentive Plan, as amended and restated effective as of March 1, 1999 (incorporated by reference to Exhibit 10.60 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 1999).
- 4.5 Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-4 (No. 333-60647), as amended, which became effective on August 21, 1998).
- 4.6 Amended and Restated Rights Agreement, dated as of May 20, 1999, between the Company and American Stock Transfer and Trust Company (including the form of Rights Certificate) (incorporated by reference to Exhibit 4.1 of the Company's Post-Effective Amendment No. 2 to Registration Statement on Form 8-A/A dated May 20, 1999).
- 4.7 Certificate of Designations of Series A Junior Participating Preferred Stock (incorporated by reference to Exhibit 4.2 of the Company's Current Report on Form 8-K dated December 14, 1998).

- 4.8* Form of Incentive Stock Option Agreement
- 4.9* Form of Non-Qualified Stock Option Agreement
- 4.10* Form of Performance Share Agreement
- 4.11 Employment Agreement, dated as of December 2, 1998, between the Company and Richard H. Friedman (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1998)
- 4.12 Employment Agreement, dated as of April 17, 1998, between the Company and Scott R. Yablon (incorporated by reference to Exhibit 10.49 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 1998)
- 5.1* Opinion of Barry A. Posner, Esq.
- 23.1* Consent of Arthur Andersen LLP.
- 23.2 Consent of Barry A. Posner, Esq. (contained in Exhibit 5.1 hereto).

- -----
* Filed herewith.

Item 9. Undertakings.

A. The undersigned registrant hereby undertakes:

(1) (i) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933 (the "Securities Act");

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. The foregoing notwithstanding, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high and of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

(2) That, for the purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

B. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the DGCL, the Certificate of Incorporation, the By-Laws or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the Village of Elmsford, State of New York, on this 27th day of May, 1999.

MIM Corporation

By: /s/ Barry A. Posner

Barry A. Posner
Vice President and General Counsel

II-6

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature -----	Capacity(ies) -----	Date ----
/s/ Richard H. Friedman ----- Richard H. Friedman	Principal Executive Officer/Director	May 26, 1999
/s/ Scott R. Yablon ----- Scott R. Yablon	Director	May 26, 1999
/s/ Edward J. Sitar ----- Edward J. Sitar	Principal Financial and Accounting Officer	May 26, 1999
/s/ Louis DiFazio ----- Louis DiFazio, Ph.D.	Director	May 26, 1999
/s/ Richard A. Cirillo ----- Richard A. Cirillo	Director	May 26, 1999
/s/ Louis A. Luzzi ----- Louis A. Luzzi, Ph.D.	Director	May 26, 1999
/s/ Michael Kooper ----- Michael Kooper	Director	May 26, 1999

INCENTIVE STOCK OPTION AGREEMENT

INCENTIVE STOCK OPTION AGREEMENT (the "Agreement") made as of the ____ day of _____, 1999 (the "Grant Date"), between MIM Corporation, a Delaware corporation (the "Company"), and _____ (the "Awardee").

WHEREAS the Company desires to afford the Awardee an opportunity to purchase shares of common stock of the Company ("Common Stock") as hereinafter provided, in accordance with the provisions of the MIM Corporation 1996 Stock Incentive Plan, as amended and restated effective December 1, 1998, a copy of which is attached (the "Plan").

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration the legal sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound hereunder, agree as follows:

1. Grant of Option. The Company hereby grants to the Awardee the right and option (the "Option") to purchase all or any part of an aggregate of _____ shares of the \$.0001 par value per share common stock ("Common Stock") of the Company (the "Shares"). The Option is in all respects limited and conditioned as hereinafter provided, and is subject to the terms and conditions of the Plan now in effect and as they may be amended from time to time, (which terms and conditions are and automatically shall be incorporated herein by reference and made a part hereof and shall control in the event of any conflict with any other terms of this Option Agreement). It is intended to the maximum extent permitted that the Option granted hereunder be an incentive stock option ("ISO") as such term is defined in Section 422 of the Internal Revenue Code of 1986, as amended (the "Code").

2. Definitions. For purposes of this Agreement, the terms used herein shall be defined as follows:

(a) Date of Termination. The Awardee's "Date of Termination" shall be the first day occurring on or after the Grant Date on which the Awardee's Employment by the Company and its Subsidiaries and Affiliates is terminated, regardless of the reason for the termination of Employment; provided that a termination of Employment shall not be deemed to occur by reason of a transfer of the Awardee between any of the Company and its Subsidiaries and Affiliates; and further provided that the Awardee's employment shall not be considered terminated while the Awardee is on a leave of absence from the Company or a Subsidiary or Affiliate approved by the Awardee's employer.

(b) Disability. The term "Disability" shall have the meaning provided in Section 22(e)(3) of the Code.

(c) Termination Without Cause or For Good Reason. The term "Termination without Cause or for Good Reason" shall mean the termination of the Awardee's Employment by the Company and its Subsidiaries and Affiliates for reasons other than "Cause" or by the Awardee for

"Good Reason," as such quoted terms are defined in the Employment Agreement between the Company and the Awardee. [If not defined in the Employment Agreement or there is no Employment Agreement, a definition will need to be inserted.]

(d) Plan Definitions. Except where the context clearly implies or indicates the contrary, a word, term, or phrase used in the Plan shall have the same meaning where used in this Agreement.

3. Purchase Price. The purchase price per share of the Shares under the Option shall be \$_____ (the "Option Price"), being equal to the Fair Market Value of Common Stock on the Grant Date (110% of Fair Market Value in the case of a 10% stockholder).

4. Term. Unless earlier terminated pursuant to any provision of the Plan or of this Option Agreement, this Option shall expire on the date (the "Expiration Date") which is the tenth anniversary of _____, 1999 (the "Reference Date"). This Option shall not be exercisable on or after the Expiration Date.

5. Exercise of Option. (a) This Option shall vest and may be exercised as to one-third of the Shares (rounded to the nearest whole share) on each of the first three anniversaries of the Grant Date, so that the Option shall be exercisable as to all Shares on the third such anniversary, provided, however, that the Option shall be exercisable (i) as to all vested Shares (that have not been previously forfeited) as of the Awardee's Date of Termination if such termination occurs by reason of the Awardee's death or Disability (ii) as to all vested and unvested Shares (that have not been previously forfeited) as of the Awardee's Date of Termination if such termination occurs by reason of the Awardee's Termination without Cause or Termination for Good Reason or (iii) as to all vested and unvested Shares (that have not been previously forfeited) as of the date of a Change in Control if the Awardee's Employment is terminated within one year following such Change in Control if such termination is without Cause or if it is for Good Reason. Options that become exercisable in accordance with the foregoing shall remain exercisable, subject to the provisions contained in the Plan and in this Option Agreement, until the expiration of the term of this Option as set forth in Paragraph 4 or until other termination of the Option.

(b) To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which ISOs are exercisable for the first time by the Awardee during any calendar year (under the Plan and all other plans of the Company and its subsidiaries, if any) exceeds \$100,000, the options or portions thereof which exceed the limit (according to the order in which they were granted) shall be treated as nonstatutory stock options.

6. Method of Exercising Option. Subject to the terms and conditions of this Option Agreement and the Plan, the Option may be exercised upon written notice to the Company at its principal office, which is located at 100 Clearbrook Road, Elmsford, New York 10523. Such notice (a suggested form of which is attached) shall state the election to exercise the Option and the number of Shares with respect to which it is being exercised; shall be signed by the person or persons so exercising the Option; shall, if the Company so requests, be accompanied by the investment certificate referred to in Paragraph 7 hereof and shall be accompanied by payment of the full Option Price of such Shares.

The Option Price shall be paid to the Company:

- (a) In cash, or in its equivalent;
- (b) In Company Common Stock previously acquired by the Awardee, provided that if such shares of Common Stock were acquired through exercise of an ISO or NQSO or of an option under a similar plan, such shares have been held by the Awardee for a period of more than 12 months on the date of exercise; or
- (c) In such other manner consistent with the Plan and applicable law as from time to time may be authorized in writing by the Company with respect to such "cashless" option exercise arrangements as the Company from time to time may maintain with securities brokers. Any such arrangements and written authorizations may be terminated at any time by the Company without notice to the Awardee; or
- (d) In any combination of (a), (b) and (c) above.

In the event such Option Price is paid, in whole or in part, with shares of Common Stock, the portion of the Option price so paid shall be equal to the Fair Market Value on the date of exercise of the Option of the Common Stock surrendered in payment of such Option Price.

Upon receipt of such notice and payment, the Company, as promptly as practicable, shall deliver or cause to be delivered a certificate or certificates representing the Shares with respect to which the Option is so exercised. The certificate or certificates for the Shares as to which the Option shall have been so exercised shall be registered in the name of the person or persons so exercising the Option (or, if the Option shall be exercised by the Awardee and if the Awardee shall so request in the notice exercising the Option, shall be registered in the name of the Awardee and the Awardee's spouse, jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person or persons exercising the Option. In the event the Option shall be exercised by any person or persons after the legal disability or death of the Awardee, such notice shall be accompanied by appropriate proof of the right of such person or persons to exercise the Option. All Shares that shall be purchased upon the exercise of the Option as provided herein shall be fully paid and non-assessable by the Company.

7. Shares to be Purchased for Investment. Unless the Company has theretofore notified the Awardee that a registration statement covering the Shares to be acquired upon the exercise of the Option has become effective under the Securities Act of 1933 and the Company has not thereafter notified the Awardee that such registration is no longer effective, or unless counsel to the Company shall be otherwise satisfied that the Awardee would be permitted under applicable law to immediately resell Shares acquired upon the exercise of the Option, it shall be a condition to any exercise of this Option that the Shares acquired upon such exercise be acquired for investment and not with a view to distribution, and the person effecting such exercise shall submit to the Company

a certificate of such investment intent, together with such other evidence supporting the same as the Company may request. The Company shall be entitled to restrict the transferability of the Shares issued upon any such exercise to the extent necessary to avoid a risk of violation of the Securities Act of 1933 (or of any rules or regulations promulgated thereunder) or of any state laws or regulations. Such restrictions may, at the option of the Company, be noted or set forth in full on the share certificates.

8. Non-Transferability of Option. This Option is not assignable or transferable, in whole or in part, by the Awardee otherwise than by the laws of descent and distribution, and during the lifetime of the Awardee the Option shall be exercisable only by the Awardee or by his guardian or legal representative.

9. Termination of Option. (a) The unexercised portion of the Option (whether vested or not) shall automatically terminate and shall become null and void and be of no further force or effect upon the first to occur of the following:

(i) The Expiration Date;

(ii) The expiration of 30 days from the date that the Awardee ceases to be an employee of the Company upon termination by resignation where such resignation is not for Good Reason;

(iii) The expiration of twelve months from the date that the Optionee ceases to be an employee of the Company or any of its Subsidiaries as a result of the Awardee's death, Disability, Termination without Cause or for Good Reason;

(iv) Immediately if the Awardee ceases to be an employee of the Company or any of its Subsidiaries if such termination is for Cause.

10. Withholding of Taxes. The obligation of the Company to deliver shares of Common Stock upon the exercise of the Option shall be subject to applicable federal, state and local tax withholding requirements.

If the exercise of this Option is subject to the withholding requirements of applicable federal tax laws, the Committee may permit the Awardee, subject to the provisions of the Plan and such additional withholding rules (the "Withholding Rules") as shall be adopted by the Committee, to satisfy the minimum federal, state and local withholding tax, in whole or in part, by electing to have the Company withhold (or by returning to the Company) shares of Common Stock, which shares shall be valued, for this purpose, at their Fair Market Value on the date of exercise of the Option (or, if later, the date on which the Optionee recognizes ordinary income with respect to such exercise) (the "Determination Date"). An election to use shares of Common Stock to satisfy tax withholding requirements must be made in compliance with and subject to the Withholding Rules, and the Committee may not withhold shares in excess of the number necessary to satisfy the minimum federal, state and local income tax withholding requirements. In the event shares of Common Stock acquired

under the exercise of an ISO are used to satisfy such withholding requirement, such shares of Common Stock must have been held by the Awardee for a period of not less than the holding period described in Section 422(a)(1) of the Code on the Determination Date, or if such shares of Common Stock were acquired through exercise of a non-qualified stock option or of an option under a similar plan, such option was granted to the Awardee at least six months prior to the Determination Date.

11. Governing Law. This Option Agreement shall be construed in accordance with, and its interpretation shall be governed by applicable federal law, and otherwise by the laws of the State of Delaware.

12. Administration. The authority to manage and control the operation and administration of this Agreement shall be vested in the Committee, and the Committee shall have all powers with respect to this Agreement as it has with respect to the Plan. Any interpretation of this Agreement by the Committee and any decision made by it with respect to this Agreement is final and binding.

13. Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior contracts and other agreements to the extent of any discrepancies contained between this document and such other document (including, without limitation, sections 5.2(b)(iii) and 5.2(c)(iii) of the Employment Agreement).

IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed by its officers thereunto duly authorized, and the Awardee has hereunto set his hand and seal, all on the day and year first above written.

MIM Corporation

By _____
Title _____

ACCEPTED AND AGREED TO:

Awardee

Notice of Exercise of Incentive Stock Option

I hereby exercise the incentive stock option granted to me on _____, 199__, by MIM Corporation, with respect to the following number of shares of the \$.0001 par value per share common stock of MIM Corporation ("Shares") covered by said option:

Number of Shares to be purchased _____

Option price per Share \$ _____

Total exercise price \$ _____

[Check one of the following to indicate method of payment:]

A. Enclosed is cash or its equivalent, in the amount of \$ _____, in full payment for such Shares.

B. Enclosed is/are _____ Share(s) with a total Fair Market Value of \$ _____ on the date hereof in full

payment for such Shares.

C. [Describe any other payment alternatives then available.]

D. Enclosed is cash or its equivalent in the amount of \$ _____, and _____ Share(s) with a total Fair Market Value of \$ _____ on the date hereof, in [partial] [full] payment for such Shares.

Please have the certificate or certificates representing the purchased Shares registered in the following name or names(1) _____ and sent to _____.

DATED: _____, _____.

Awardee's Signature

(1) Certificates may be registered in the name of the Awardee alone or in the names of the Awardee and his or her spouse, jointly, with right of survivorship.

NON-QUALIFIED STOCK OPTION AGREEMENT

NON-QUALIFIED STOCK OPTION AGREEMENT (the "Agreement") made as of the _____ day of _____, 1999 (the "Grant Date"), between MIM Corporation, a Delaware corporation (the "Company"), and _____ (the "Awardee").

WHEREAS the Company desires to afford the Awardee an opportunity to purchase shares of common stock of the Company ("Common Stock") as hereinafter provided, in accordance with the provisions of the MIM Corporation 1996 Stock Incentive Plan, as amended and restated effective December 1, 1998, a copy of which is attached (the "Plan").

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration the legal sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound hereunder, agree as follows:

1. Grant of Option. The Company hereby grants to the Awardee the right and option (the "Option") to purchase all or any part of an aggregate of _____ shares of the \$.0001 par value per share common stock ("Common Stock") of the Company (the "Shares"). The Option is in all respects limited and conditioned as hereinafter provided, and is subject to the terms and conditions of the Plan now in effect and as they may be amended from time to time (which terms and conditions are and automatically shall be incorporated herein by reference and made a part hereof and shall control in the event of any conflict with any other terms of this Option Agreement). It is intended that the Option granted hereunder be a non-qualified stock option ("NQSO") and not an incentive stock option ("ISO") as such term is defined in Section 422 of the Internal Revenue Code of 1986, as amended (the "Code").

2. Definitions. For purposes of this Agreement, the terms used herein shall be defined as follows:

(a) Date of Termination. The Awardee's "Date of Termination" shall be the first day occurring on or after the Grant Date on which the Awardee's Employment by the Company and its Subsidiaries and Affiliates is terminated, regardless of the reason for the termination of Employment; provided that a termination of Employment shall not be deemed to occur by reason of a transfer of the Awardee between any of the Company and its Subsidiaries and Affiliates; and further provided that the Awardee's employment shall not be considered terminated while the Awardee is on a leave of absence from the Company or a Subsidiary or Affiliate approved by the Awardee's employer.

(b) Disability. The term "Disability" shall have the meaning provided in Section 22(e)(3) of the Code.

(c) Termination Without Cause or For Good Reason. The term "Termination

without Cause or for Good Reason" shall mean the termination of the Awardee's Employment by the Company and its Subsidiaries and Affiliates for reasons other than "Cause" or by the Awardee for "Good Reason," as such quoted terms are defined in the Employment Agreement between the Company and the Awardee. [If not defined in the Employment Agreement or there is no Employment Agreement, a definition will need to be inserted.]

(d) Plan Definitions. Except where the context clearly implies or indicates the contrary, a word, term, or phrase used in the Plan shall have the same meaning where used in this Agreement.

3. Purchase Price. The purchase price per share of the Shares under the Option shall be \$_____ (the "Option Price"), being equal to the Fair Market Value of Common Stock on the Grant Date.

4. Term. Unless earlier terminated pursuant to any provision of the Plan or of this Option Agreement, this Option shall expire on the date (the "Expiration Date") which is the tenth anniversary of _____, 1999 (the "Reference Date"). This Option shall not be exercisable on or after the Expiration Date.

5. Exercise of Option. This Option shall vest and may be exercised as to one-third of the Shares (rounded to the nearest whole share) on each of the first three anniversaries of the Grant Date, so that the Option shall be exercisable as to all Shares on the third such anniversary, provided, however, that the Option shall be exercisable (i) as to all vested Shares (that have not been previously forfeited) as of the Awardee's Date of Termination if such termination occurs by reason of the Awardee's death or Disability (ii) as to all vested and unvested Shares (that have not been previously forfeited) as of the Awardee's Date of Termination if such termination occurs by reason of the Awardee's Termination without Cause or Termination for Good Reason or (iii) as to all vested and unvested Shares (that have not been previously forfeited) as of the date of a Change in Control if the Awardee's Employment is terminated within one year following such Change in Control if such termination is without Cause or if it is for Good Reason. Options that become exercisable in accordance with the foregoing shall remain exercisable, subject to the provisions contained in the Plan and in this Option Agreement, until the expiration of the term of this Option as set forth in Paragraph 4 or until other termination of the Option.

6. Method of Exercising Option. Subject to the terms and conditions of this Option Agreement and the Plan, the Option may be exercised upon written notice to the Company at its principal office, which is located at 100 Clearbrook Road, Elmsford, NY 10523. Such notice (a suggested form of which is attached) shall state the election to exercise the Option and the number of Shares with respect to which it is being exercised; shall be signed by the person or persons so exercising the Option; shall, if the Company so requests, be accompanied by the investment certificate referred to in Paragraph 7 hereof and shall be accompanied by payment of the full Option Price of such Shares.

The Option Price shall be paid to the Company:

(a) In cash, or in its equivalent;

(b) In Company Common Stock previously acquired by the Awardee, provided that if such shares of Common Stock were acquired through exercise of an ISO or NQSO or of an option under a similar plan, such shares have been held by the Awardee for a period of more than 12 months on the date of exercise; or

(c) In such other manner consistent with the Plan and applicable law as from time to time may be authorized in writing by the Company with respect to such "cashless" option exercise arrangements as the Company from time to time may maintain with securities brokers. Any such arrangements and written authorizations may be terminated at any time by the Company without notice to the Awardee.

(d) In any combination of (a), (b) and (c) above.

In the event such Option Price is paid, in whole or in part, with shares of Common Stock, the portion of the Option Price so paid shall be equal to the Fair Market Value on the date of exercise of the Option of the Common Stock surrendered in payment of such Option Price.

Upon receipt of such notice and payment, the Company, as promptly as practicable, shall deliver or cause to be delivered a certificate or certificates representing the Shares with respect to which the Option is so exercised. The certificate or certificates for the Shares as to which the Option shall have been so exercised shall be registered in the name of the person or persons so exercising the Option (or, if the Option shall be exercised by the Awardee and if the Awardee shall so request in the notice exercising the Option, shall be registered in the name of the Awardee and the Awardee's spouse, jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person or persons exercising the Option. In the event the Option shall be exercised by any person or persons after the legal disability or death of the Awardee, such notice shall be accompanied by appropriate proof of the right of such person or persons to exercise the Option. All Shares that shall be purchased upon the exercise of the Option as provided herein shall be fully paid and non-assessable by the Company.

7. Shares to be Purchased for Investment. Unless the Company has theretofore notified the Awardee that a registration statement covering the Shares to be acquired upon the exercise of the Option has become effective under the Securities Act of 1933 and the Company has not thereafter notified the Awardee that such registration is no longer effective, or unless counsel to the Company shall be otherwise satisfied that the Awardee would be permitted under applicable law to immediately resell Shares acquired upon the exercise of the Option, it shall be a condition to any exercise of this Option that the Shares acquired upon such exercise be acquired for investment and not with a view to distribution, and the person effecting such exercise shall submit to the Company a certificate of such investment intent, together with such other evidence supporting the same as the Company may request. The Company shall be entitled to restrict the transferability of the Shares issued upon any such exercise to the extent necessary to avoid a risk of violation of the Securities Act of 1933 (or of any rules or regulations promulgated thereunder) or of any state laws or regulations.

Such restrictions may, at the option of the Company, be noted or set forth in full on the share certificates.

8. Non-Transferability of Option. This Option is not assignable or transferable, in whole or in part, by the Awardee otherwise than by the laws of descent and distribution, and during the lifetime of the Awardee the Option shall be exercisable only by the Awardee or by his guardian or legal representative.

9. Termination of Option. (a) The unexercised portion of the Option (whether vested or not) shall automatically terminate and shall become null and void and be of no further force or effect upon the first to occur of the following:

- (i) The Expiration Date;
- (ii) The expiration of 30 days from the date that the Awardee ceases to be an employee of the Company upon termination by resignation where such resignation is not for Good Reason;
- (iii) The expiration of twelve months from the date that the Optionee ceases to be an employee of the Company or any of its Subsidiaries as a result of the Awardee's death, Disability, Termination without Cause or for Good Reason;
- (iv) Immediately if the Awardee ceases to be an employee of the Company or any of its Subsidiaries if such termination is for Cause.

10. Withholding of Taxes. The obligation of the Company to deliver shares of Common Stock upon the exercise of the Option shall be subject to applicable federal, state and local tax withholding requirements.

If the exercise of this Option is subject to the withholding requirements of applicable federal tax laws, the Committee may permit the Awardee, subject to the provisions of the Plan and such additional withholding rules (the "Withholding Rules") as shall be adopted by the Committee, to satisfy the minimum federal, state and local withholding tax, in whole or in part, by electing to have the Company withhold (or by returning to the Company) shares of Common Stock, which shares shall be valued, for this purpose, at their Fair Market Value on the date of exercise of the Option (or, if later, the date on which the Optionee recognizes ordinary income with respect to such exercise) (the "Determination Date"). An election to use shares of Common Stock to satisfy tax withholding requirements must be made in compliance with and subject to the Withholding Rules, and the Committee may not withhold shares in excess of the number necessary to satisfy the minimum federal, state and local income tax withholding requirements. In the event shares of Common Stock acquired under the exercise of an ISO are used to satisfy such withholding requirement, such shares of Common Stock must have been held by the Awardee for a period of not less than the holding period described in Section 422(a)(1) of the Code on the Determination Date, or if such shares of Common

Stock were acquired through exercise of a non-qualified stock option or of an option under a similar plan, such option was granted to the Awardee at least six months prior to the Determination Date.

11. Governing Law. This Option Agreement shall be construed in accordance with, and its interpretation shall be governed by applicable federal law, and otherwise by the laws of the State of Delaware.

12. Administration. The authority to manage and control the operation and administration of this Agreement shall be vested in the Committee, and the Committee shall have all powers with respect to this Agreement as it has with respect to the Plan. Any interpretation of this Agreement by the Committee and any decision made by it with respect to this Agreement is final and binding.

13. Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior contracts and other agreements to the extent of any discrepancies contained between this document and such other document (including, without limitation, sections 5.2(b)(iii) and 5.2(c)(iii) of the Employment Agreement).

IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed by its officers thereunto duly authorized, and the Awardee has hereunto set his hand and seal, all on the day and year first above written.

MIM Corporation

By _____
Title _____

ACCEPTED AND AGREED TO:

Awardee

Notice of Exercise of Non-Qualified Stock Option

I hereby exercise the non-qualified stock option granted to me on _____, 199__, by MIM Corporation, with respect to the following number of shares of the \$.0001 par value per share common stock of MIM Corporation ("Shares") covered by said option:

Number of Shares to be purchased _____
Option price per Share \$ _____
Total exercise price \$ _____

[Check one of the following to indicate method of payment:]

- A. Enclosed is cash or its equivalent, in the amount of \$ _____, in full payment for such Shares.
- B. Enclosed is/are _____ Share(s) with a total Fair Market Value of \$ _____ on the date hereof in full payment for such Shares.
- C. [Describe any other payment alternatives then available.]
- D. Enclosed is cash or its equivalent in the amount of \$ _____, and _____ Share(s) with a total Fair Market Value of \$ _____ on the date hereof, in [partial] [full] payment for such Shares.

Please have the certificate or certificates representing the purchased Shares registered in the following name or names _____ and sent to _____.

DATED: _____, _____.

Awardee's Signature

(1) Certificates may be registered in the name of the Awardee alone or in the names of the Awardee and his or her spouse, jointly, with right of survivorship.

PERFORMANCE SHARES AGREEMENT

PERFORMANCE SHARES AGREEMENT (the "Agreement") made as of the ____ day of _____, 1999 (the "Grant Date"), between MIM Corporation, a Delaware corporation (the "Company"), and _____ (the "Awardee").

WHEREAS, the Company desires to afford the Awardee an opportunity to own shares of the common stock of the Company, par value \$.0001 per share ("Common Shares"), as hereinafter provided, in accordance with the provisions of the MIM Corporation 1996 Stock Incentive Plan, as amended and restated effective December 1, 1998, a copy of which is attached (the "Plan").

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration the legal sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound hereunder, agree as follows:

1. Grant of Restricted Shares. The Company hereby grants to the Awardee an aggregate of _____ Common Shares (the "Performance Shares"), the effectiveness of which grant is contingent in all respects upon approval of the Plan by the shareholders of the Company on or before _____. The grant is in all respects limited and conditioned as hereinafter provided, and is subject to the terms and conditions of the Plan now in effect and as they may be amended from time to time (which terms and conditions are and automatically shall be incorporated herein by reference and made a part hereof and shall control in the event of any conflict with any other terms of this Performance Shares Agreement).

2. Vesting and Forfeiture. If the Awardee's Date of Termination does not occur during the Restricted Period, then, at the end of the Restricted Period, the Awardee shall become vested in all of the Performance Shares. If (a) the Company meets the target Earnings Per Share for the year 2001 (as reflected on Exhibit 1 attached hereto) and (b) the Awardee's Date of Termination does not occur prior to December 31, 2001, then the Awardee shall become vested in all of the Performance Shares upon closing of the Company's financial statements for the year 2001 (the "Accelerated Vesting Date"). If the Awardee does not meet the requirements for vesting contained in this paragraph, the Awardee shall immediately forfeit all of the Performance Shares, except to the extent provided as follows:

(a) If the Awardee's Date of Termination occurs by reason of the Awardee's death, Disability or by reason of Termination without Cause or Termination for Good Reason, the Awardee shall become immediately vested, as of the Date of Termination, in (i) 1/3 of the Performance Shares if the Date of Termination occurs before the first anniversary of the Grant Date and the Company achieves the target Earnings Per Share (as reflected on Exhibit 1) for the fiscal year in which the Date of Termination occurs; (ii) 2/3 of the Performance Shares if the Date of Termination occurs on or after the first anniversary but before the second anniversary of the Grant Date and the Company achieves the target Earnings Per Share (as reflected on Exhibit 1) for the fiscal year in which the Date of Termination occurs; and, (iii) all of the Performance Shares if the Date of Termination occurs on or after the second anniversary but before the day following the third anniversary of the Grant Date

and the Company achieves the target Earnings Per Shares (as reflected on Exhibit 1) for the fiscal year in which the Date of Termination occurs.

(b) The Awardee shall become vested in all of the Performance Shares as of the Date of Termination if the Awardee's Employment is terminated within one year following such Change in Control (provided such termination occurs prior to the end of the Restricted Period and such termination is a Termination without Cause or is a Termination for Good Reason).

If the Awardee is at any time Terminated for Cause or if the Awardee resigns without Good Reason, the Awardee shall forfeit all Performance Shares that have not previously vested.

3. Delivery of Restricted Stock. As soon as practicable after the first to occur of (a) the expiration of the Restricted Period, (b) the Awardee's Date of Termination and (c) the date of a Change in Control, the Committee shall certify in writing as to whether or not the performance objectives have been satisfied. If the Committee certifies that the performance objectives have been satisfied, or determines that Performance Shares otherwise have vested, the restrictions applicable to such Performance Shares shall lapse and a certificate for the number of Common Shares with respect to which the restrictions have lapsed shall be delivered to the Awardee free and clear of all such restrictions.

4. Transfers. Performance Shares may not be sold, assigned, transferred, pledged or otherwise encumbered until the Awardee is vested in the shares and then only to the extent the Awardee is vested in the shares.

5. Dividends and Voting Rights. The Awardee shall be entitled to receive any regular cash dividends paid with respect to Performance Shares that become payable during the Restricted Period; provided, however, that no such dividends shall be payable to or for the benefit of the Awardee with respect to record dates occurring prior to the Grant Date, or with respect to record dates occurring on or after the date, if any, on which the Awardee has forfeited Performance Shares; and provided further that all distributions made with respect to the Performance Shares as a result of any split, distribution or combination of Performance Shares or other similar transaction shall be deemed to be Performance Shares subject to the provisions of this Agreement. The

Awardee shall be entitled to vote the Performance Shares during the Restricted Period to the same extent as would have been applicable to the Awardee if the Awardee was then vested in the shares; provided, however, that the Awardee shall not be entitled to vote the shares with respect to record dates for such voting rights arising prior to the Grant Date, or with respect to record dates occurring on or after the date, if any, on which the Awardee has forfeited the Performance Shares.

6. Deposit of Performance Shares. Each certificate issued in respect of Performance Shares granted under this Agreement shall be registered in the name of the Awardee and shall be deposited with the Company. The grant of Performance Shares is conditioned upon the Awardee endorsing in blank a stock power for the Performance Shares and delivering such stock power to the depository designated by the Committee contemporaneously with the issuance and deposit of the Performance Shares with the Company.

7. Definitions. For purposes of this Agreement, the terms used in this Agreement shall be defined as follows:

(a) Date of Termination. The Awardee's "Date of Termination" shall be the first day occurring on or after the Grant Date on which the Awardee's Employment by the Company and its Subsidiaries and Affiliates is terminated, regardless of the reason for the termination of Employment; provided that a termination of Employment shall not be deemed to occur by reason of a transfer of the Awardee between any of the Company and its Subsidiaries and Affiliates; and further provided that the Awardee's employment shall not be considered terminated while the Awardee is on a leave of absence from the Company or a Subsidiary or Affiliate approved by the Awardee's employer.

(b) Designated Beneficiary. The term "Designated Beneficiary" means the beneficiary or beneficiaries designated by the Awardee in a writing filed with the Committee in such form and at such time as the Committee shall require.

(c) Disability. The term "Disability" shall have the meaning provided in Section 22(e)(3) of the Code.

(d) Restricted Period. The term "Restricted Period" means the period commencing on the Grant Date and ending on December 31, 2006.

(e) Termination Without Cause or For Good Reason. The term "Termination without Cause or for Good Reason" shall mean the termination of the Awardee's Employment by the Company and its Subsidiaries and Affiliates for reasons other than "Cause" or by the Awardee for "Good Reason," as such quoted terms are defined in the Employment Agreement between the Company and the Awardee. [If not defined in the Employment Agreement or there is no Employment Agreement, a definition will need to be inserted.]

(f) Plan Definitions. Except where the context clearly implies or indicates the contrary, a word, term, or phrase used in the Plan shall have the same meaning where used in this Agreement.

8. Shares Acquired for Investment. The Awardee hereby represents that the Performance Shares are being acquired for investment for the Awardee's own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof. The Awardee understands that the Performance Shares have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state by reason of exemptions from the registration provisions of the Securities Act and such laws which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Awardee's representations as expressed herein.

9. Withholding of Taxes. Any obligation of the Company to deliver Common Shares pursuant to this Agreement shall be subject to applicable federal, state and local withholding tax requirements. The Company shall have the right to require recipients or their beneficiaries or legal

representatives to remit to the Company an amount sufficient to satisfy such withholding tax requirements, or to deduct from all payments to be made hereunder amounts sufficient to satisfy all such withholding tax requirements. The Committee may, in its sole discretion, permit a recipient to satisfy his or her tax withholding obligation either by (i) surrendering Common Shares owned by the recipient or (ii) having the Company withhold from Common Shares otherwise deliverable to the Awardee. Shares surrendered or withheld shall be valued at their Fair Market Value as of the date on which income is required to be recognized for income tax purposes. The Awardee hereby agrees that he will not make an election under Section 83(b) of the Code with respect to any or all of the Performance Shares.

10. Heirs and Successors. This Agreement shall be binding upon, and inure to the benefit of, the Company and its successors and assigns, and upon any person acquiring, whether by merger, consolidation, purchase of assets or otherwise, all or substantially all of the Company's assets and business. If any rights of the Awardee or benefits distributable to the Awardee under this Agreement have not been exercised or distributed, respectively, at the time of the Awardee's death, such rights shall be exercisable by the Designated Beneficiary, and such benefits shall be distributed to the Designated Beneficiary, in accordance with the provisions of this Agreement and the Plan. If a deceased Awardee fails to designate a beneficiary, or if the Designated Beneficiary does not survive the Awardee, any rights that would have been exercisable by the Awardee and any benefits distributable to the Awardee shall be exercised by or distributed to the legal representative of the estate of the Awardee. If a deceased Awardee designates a beneficiary but the Designated Beneficiary dies before the Designated Beneficiary's exercise of all rights under this Agreement or before the complete distribution of benefits to the Designated Beneficiary under this Agreement, then any rights that would have been exercisable by the Designated Beneficiary shall be exercised by the legal representative of the estate of the Designated Beneficiary, and any benefits distributable to the Designated Beneficiary shall be distributed to the legal representative of the estate of the Designated Beneficiary.

11. Governing Law. This Agreement shall be construed in accordance with, and its interpretation shall be governed by applicable federal law, and otherwise by the laws of the State of Delaware.

12. Administration. The authority to manage and control the operation and administration of this Agreement shall be vested in the Committee, and the Committee shall have all powers with respect to this Agreement as it has with respect to the Plan. Any interpretation of this Agreement by the Committee and any decision made by it with respect to this Agreement is final and binding.

13. Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior contracts and other agreements to the extent of any discrepancies contained between this document and such other document (including, without limitation, sections 5.2(c) (v) and 5.1(c) (iii) of the Employment Agreement).

IN WITNESS WHEREOF, the Company has caused this Performance Shares Agreement to be duly executed by its officers thereunto duly authorized, and the Awardee has hereunto set his hand and seal, all on the day and year first above written.

MIM CORPORATION

By _____
Name:
Title:

ACCEPTED AND AGREED TO:

Awardee

MIM Corporation
100 Clearbrook Road
Elmsford, NY 10523

May 27, 1999

MIM Corporation
100 Clearbrook Road
Elmsford, NY 10523

Ladies and Gentlemen:

I am the general counsel of MIM Corporation, a Delaware corporation (the "Company"), and have represented the Company as such in connection with the preparation and filing with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Act"), of a Registration Statement on Form S-8 of the Company (the "Registration Statement") covering 2,100,000 shares (the "Shares") of the Common Stock, \$0.0001 par value per share, of the Company, of which 1,800,000 Shares are subject to options previously granted by the Company to two executive officers of the Company under employment agreements with the Company, and 300,000 of which represent Shares issued by the Company to one of those executive officers under his employment agreement with the Company, which Shares are subject to restrictions on transfer and encumbrance until December 2, 2006.

In rendering the opinion set forth herein, I have examined executed copies or photocopies of: (i) the Registration Statement, the Reoffer Prospectus constituting a part of the Registration Statement and the employment agreements of the two executive officers; (ii) the Amended and Restated Certificate of Incorporation of the Company, the Amended and Restated By-laws of the Company and excerpts from the minute books of the Company; (iii) the current forms of Incentive Stock Option Agreement, Non-Qualified Stock Option Agreement and Performance Share Agreement (collectively, the "Agreements"); and (iv) such other records, documents, certificates and other instruments as in my judgment is necessary or appropriate as a basis for my opinion expressed below. I have knowledge of all proceedings heretofore taken and am familiar with the proceedings proposed to be taken by the Company in connection with the authorization and issuance of the Shares.

Based upon the foregoing, and in reliance thereon, and subject to the qualifications, assumptions and exceptions set forth herein, I am of the opinion that upon the issuance of the Shares in accordance with the applicable provisions of the employment agreements, and in accordance with the terms of any Agreement entered into pursuant to the terms and conditions of the employment

- 10 -

agreements, and as contemplated by the Registration Statement, the Shares will be validly issued, fully paid and non-assessable.

The foregoing does not express, or purport to express, any opinion with respect to the laws of any jurisdiction other than the laws of the State of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United States of America.

I hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the use of my name under the heading "Legal Matters" in the Registration Statement and the Reoffer Prospectus which forms a part thereof. In giving this consent, I do not hereby admit that I am within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations promulgated thereunder by the Commission. This opinion is given as of the date hereof and I assume no obligation to update or supplement this opinion to reflect any facts or circumstances which may occur after the date of this opinion.

Respectfully submitted,

Barry A. Posner
General Counsel

- 11 -

CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

As independent public accountants, we hereby consent to the incorporation by reference in this registration statement on Form S-8 of our report dated February 12, 1999 (except with respect to the matter described in Note 7 as to which the date is March 31, 1999) included in MIM Corporation's Form 10-K for the year ended December 31, 1998 and to all references to our firm, included in or made part of this registration statement.

ARTHUR ANDERSEN LLP

Roseland, New Jersey
May 21, 1999